



Cynllun Cynorthwyo Gwaed
Heintiedig Cymru
Wales Infected Blood
Support Scheme

FORM L

APPLICATIONS FOR CHRONIC AND ADVANCED HEPATITIS C PAYMENT WHERE THE INFECTED PERSON IS DECEASED

SECTION 1 (A) DATA PROTECTION AND APPLICANT'S DECLARATION



Please tick to confirm

☐

I understand that data I provide may be shared with NHS service providers and Counter Fraud Services to ensure accurate and timely payment and for the purposes or prevention, detection and investigation of crime.

DECLARATION BY APPLICANT

I agree that the information I give on this form is complete and correct.

I agree to repay any money I receive to which it is found that I am no longer entitled.

I understand if I knowingly give wrong or incomplete information I may be prosecuted.

I confirm that I am the sole Executor of the estate of the deceased person this application relates to, or I am making this application on behalf of all the appointed Executors of the estate.

I agree to NHS Wales obtaining any data held on the deceased person this applications relates to from the Skipton Fund or the Caxton Foundation for the purposes of providing me with financial support.

I understand that NHS Wales may require to access data held on the deceased person by other public bodies and/or make any additional enquiries with other public bodies that may be necessary in order to reach a decision regarding this application.

Signature of
Applicant

Date

HOW WE USE YOUR INFORMATION

The personal information that you provide on this form will only be used by Velindre NHS Trust for the purposes of checking your eligibility for a payment and to administer your application. By submitting this form to a medical professional, you consent to the deceased person's medical details requested in Sections 1 to 6 inclusive being supplied to Velindre NHS Trust for the purpose of administering your application.

In the event of a dispute as to your eligibility for payment, your information may be disclosed to the Appeals Panel. If your application is deemed to be ineligible, Velindre NHS Trust may keep your application form on file so that we have a full historical record in the event that you lodge an appeal or if you reapply for a payment at a later stage, in any event information we hold about you will be held for the purpose we collected it and kept for at least six years.

Your information and the deceased person's will be held in the strictest confidence and will be kept securely, in accordance with the Data Protection Act 1998, and will not be shared with any other organisation. Velindre NHS Trust are a Data Controller under the Act in respect of the personal information which we collect about you. We have notified the Information Commissioner of our data processing activities and our registration number is Z5021900.

If you have any questions regarding the use of your information, or have any concerns with how your information is being processed, or wish to obtain a copy of information held by us about you, please contact us by writing to Velindre Cancer Centre, Velindre Road, Whitchurch, Cardiff, CF14 2TL

SECTION 1 (B) APPLICATION DETAILS

The person completing this form must be an Executor of the deceased person's estate.

Please provide your details here:

Title	<input type="text"/>	First Name	<input type="text"/>
Middle Name(s)	<input type="text"/>	Surname	<input type="text"/>
Address	<input type="text"/>		
	<input type="text"/>		
	<input type="text"/>	Post Code	<input type="text"/>
Main Telephone	<input type="text"/>	Mobile Telephone	<input type="text"/>

SECTION 1 (C) DECEASED PERSON'S DETAILS

Please provide details of the deceased person that the application relates to:

Title	<input type="text"/>	First Name	<input type="text"/>
Middle Name(s)	<input type="text"/>	Surname	<input type="text"/>
Previous Names	<input type="text"/>		
Address (their	<input type="text"/>		
	<input type="text"/>		
Main residence at the date of death)	<input type="text"/>	Post Code	<input type="text"/>
Date of Birth	<input type="text"/>	Date of Death	<input type="text"/>

SECTION 1 (D) DECEASED PERSON'S ESTATE

Did the deceased person leave a will? Yes ☐ No ☐

Has a grant of representation been requested for the deceased person's estate? Yes ☐ No ☐

If 'Yes', has the grant of representation been granted? Yes ☐ No ☐

Is there anyone else who might apply to the scheme for a payment in respect of the deceased person? Yes ☐ No ☐

If 'Yes', please provide their details:

Title First Name

Middle Name(s) Surname

Address

 Post Code

Date of Birth Date of Death

What was their relationship to the deceased person?

Why do you feel this person might apply to the scheme?

SECTION 1 (E)

ADDITIONAL APPLICATION DETAILS

Do you believe the deceased person was infected with Hepatitis C as a result of treatment they received themselves with NHS blood, tissue, or blood products? Yes ☐ No ☐

If 'Yes', please provide as much information as you can on how you believe the infection occurred

Alternatively, do you believe they were infected with Hepatitis C as a result of the virus being transmitted from someone else, who themselves were infected as a result of treatment with NHS blood, tissue, or blood products? Yes ☐ No ☐

If 'Yes', please provide further details below:

Firstly, how do you believe the infection occurred?

Secondly, who do you believe the deceased person received the infection from?

Title	<input type="text"/>	First Name	<input type="text"/>
Middle Name(s)	<input type="text"/>	Surname	<input type="text"/>
Address	<input type="text"/>		
	<input type="text"/>		
	<input type="text"/>	Post Code	<input type="text"/>

What was the deceased
person's relationship to this
person?

SECTION 1 (F) ADDITIONAL INFORMATION

If you have any additional information you would like to provide, please add it here:

Once you have completed all parts of Section 1, please pass the form to a medical professional to complete.

The medical professional will complete the remainder of the form and return it directly to the Wales Infected Blood Support Scheme on your behalf.

THE FOLLOWING SECTIONS MUST BE COMPLETED BY A MEDICAL PROFESSIONAL

GUIDANCE NOTES FOR MEDICAL PROFESSIONALS

Thank you for your help with this application. In most cases this form will concern a deceased person who is known to you and who had been infected with Hepatitis C.

Sections 2-5 of this form should be completed in all cases. The purpose of these sections is:

- To confirm that the deceased person had been chronically infected with stage I Hepatitis C

AND

- To confirm that the infection most probably arose through treatment with NHS blood, tissue or blood products

If there are questions in this form relating to the deceased person that you cannot answer, please consult other medical professionals who have treated the deceased person and who would be able to provide the information.

In some cases this form will concern a deceased person who had been indirectly infected by somebody who is (or was) infected themselves through NHS treatment.

Sections 6-11 should only be completed in cases where the deceased person had developed either:

- Cirrhosis
- Primary liver cancer
- B-cell non-Hodgkin's lymphoma; or
- Had received a liver transplant, or was on the waiting list to receive one

If the deceased person's circumstances meet the above criteria, you should complete Sections 6-11 of this form, only if you are the consultant physician who was in charge of the deceased person's care.

It is intended that the existence of cirrhosis should be assessed using either existing biopsy data, or the results of non-invasive tests. A liver biopsy should not be performed purely for the purpose of making this application.

When complete, please return this form along with all relevant documents direct to the following address:

Velindre Cancer Centre
Wales Infected Blood Support Scheme
Velindre Road
Cardiff
CF14 2TL

ADDITIONAL NOTES ON THE LAYOUT AND COMPLETION OF SECTION 6-11

Section 6	<p>This section asks whether the deceased person has undergone liver transplantation, is currently awaiting a transplant, or has developed primary liver cancer.</p> <p>If any of these circumstances pertain, Sections 7-11 do not need to be completed.</p>
Section 7	<p>This section seeks information of liver histology, where available.</p> <p>Where histological proof of cirrhosis is available, Sections 6 and 8-11 do not need to be completed.</p>
Section 8	<p>This section asks whether the deceased person has developed B-cell non-Hodgkin's lymphoma.</p> <p>If this is the case, Sections 6-7 and 9-11 do not need to be completed.</p>
Section 9	<p>This section should be completed for the deceased person for whom a liver biopsy has never been performed, or without recent liver histology. It asks for the calculation of two simple indices, based upon readily available laboratory tests, which have been used to predict cirrhosis. The chosen indices require recent and repeatable measurements (two samples not less than three months apart) of the two liver enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and the platelet count. Further details of these indices are shown on the next page.</p> <p>With regards to the payment for advanced Hepatitis C, an APRI ≥ 2.0 together with an AST/ALT ≥ 1.0 will be accepted as presumptive evidence for cirrhosis provided there are no factors other than fibrosis which are potentially affecting the AST, ALT and platelet readings. Where both these indices are at or above these cut-offs, and there are no other factors other than fibrosis which may be affecting the AST, ALT and platelet readings, then Sections 10-11 do not need to be completed.</p>
Section 10	<p>This section should be completed for the deceased person whose application depends on establishing a diagnosis of cirrhosis and for whom a liver biopsy has not been performed (or has not been performed recently), and where the simple indices used in Section 9 do not predict cirrhosis, or there are other factors other than fibrosis influencing these readings. The purpose of this section is to record any other information already available that may assist the Scheme in determining whether cirrhosis is probable. This may include transient elastography (e.g. FibroScan®) results.</p>
Section 11	<p>This section must be completed in respect of the deceased person who is relying upon information supplied in Section 10 to support the application. It seeks an overall clinical opinion as to whether or not cirrhosis is probable.</p>

INDICES

i. Aspartate aminotransferase to platelet ratio index (APRI)†

This index has been developed to amplify the opposing effects of liver fibrosis on the level of aspartate aminotransferase and the platelet count.

$$APRI = \frac{(AST/ULN) \times 100}{Platelets (10^9)/L}$$

Where AST is in IU/L and ULN is in the upper limit of normal

For example, where a patient has a platelet count of 120×10^9 and an AST level of 90 (ULN = 45), the APRI is calculated as:

$$APRI = \frac{(90/45) \times 100}{120} = \frac{2 \times 100}{120} = 1.67$$

†Wai C-T, Greenson JK, Fontana RJ, Lalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS-F. A simple noninvasive index can predict both significant fibrosis and cirrhosis with chronic hepatitis C. *Hepatology* 2003; 38: 518-526

ii. Aspartate aminotransferase-alanine aminotransferase (AST/ALT) ration index ‡

This index is based upon the observation that, as chronic liver disease progresses, AST levels increase more than ALT levels.

$$Ratio = \frac{AST}{ALT}$$

Where AST and ALT are measured in IU/L

‡Giannini E, Risso D, Botta F, Choarbonello B *et al.* Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus related to chronic liver disease. *Arch Intern Med.* 2003; 163(2): 218-24.

SECTION 2 (A)

MEDICAL PROFESSIONAL'S DECLARATION



Please tick to confirm

☐

I understand that data I provide may be shared with NHS Counter Fraud Services to ensure accurate payment and for the purposes of prevention, detection and investigation of crime.

DECLARATION BY MEDICAL PROFESSIONAL

I agree that the information I give in Sections 2-11 of this form is complete and correct.

I understand that if I knowingly give or endorse wrong or incomplete information this may result in disciplinary action and I may be prosecuted.

Signature of
Medical
Professional

Date

SECTION 2 (B)

DETAILS OF MEDICAL PROFESSIONAL
COMPLETING FORM

Registered Medical Practitioner's GMC registration number
(if practising in UK)

In what capacity have you completed this form? (e.g. GP,
consultant, etc.)

How long have you known the person in respect of whom you have
completed this form?

Years Months

Your Details

Title First Name

Middle Name(s) Surname

Hospital/Surgery
Address

Post Code

Telephone E-Mail Address

If you consulted any other medical professional(s) to help you complete this form, please provide
their details here:

SECTION 3(A)

TO CONFIRM THE DECEASED PERSON'S
ELIGIBILITY FOR PAYMENT

Are there any records to suggest the deceased person or someone representing their estate had previously applied to another UK scheme (e.g. Skipton Fund) to receive payments with regards to their Hepatitis C infection?

Yes

☐

No

☐

If 'Yes', please provide details below.

Had the deceased person ever had a positive HCV antibody test?

Yes

☐

No

☐

If 'Yes', what was the date of first diagnosis?

Was the deceased person PCR/RNA positive at the time of death?

Yes

☐

No

☐

If they were PCR/RNA negative at the time of death, was this as a result of past or ongoing treatment for Hepatitis C? Yes

☐

No

☐

If the deceased person was PCR/RNA negative, is there radiological or pathological evidence that they were chronically infected after the acute phase (i.e. the first six months) of illness had passed? (Relevant radiological or pathological evidence would include chronic- phase raised liver-function tests, previous consideration for treatment, liver histology or radiotherapy, other symptoms of chronic hepatitis)

Yes

☐

No

☐

PLEASE PROVIDE A COPY OF MEDICAL RECORDS CONFIRMING ALL OF THE ANSWERS IN SECTION 3(A)

SECTION 3 (B) TO CONFIRM WHETHER INFECTION AROSE INDIRECTLY

In your opinion, is it probable the deceased person was infected as a result of transmission of the virus from another person who had themselves been infected through treatment with NHS blood, blood products, or tissue?

Yes ☐ No ☐

If 'Yes', did transmission occur as a consequence of:

- Sexual intercourse?
- Accidental needle stick?
- Mother-to-baby transmission?
- Other? (please specify)

Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
Yes	<input type="checkbox"/>	No	<input type="checkbox"/>

PLEASE PROVIDE DETAILS AND A COPY OF TEST RESULTS TO CONFIRM WHICH GENOTYPE THE DECEASED PERSON IS/WAS INFECTED WITH

If any of the answers in Section 3(B) are 'Yes', please go to Section 5(B)

SECTION 4

TO BE COMPLETED ONLY IN RESPECT OF INFECTED
PEOPLE WITH HAEMOPHILIA OR OTHER INHERITED
OR ACQUIRED BLEEDING DISORDERS

Did the deceased person have, or is a carrier of,
an inherited or acquired
bleeding disorder? (e.g. Haemophilia or Von Willebrand disease)

Yes ☐No ☐

Were any of the following used to treat the deceased person before September 1991?

- Whole blood or components (including platelets, red cells, neutrophils etc.)
- Cryoprecipitate
- Plasma/FFP

Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐

Were any of the following used to treat the deceased person before September 1991?

- Factor VIII concentrate
- Factor IX concentrate
- FEIBA
- DEFIX
- Fibrinogen
- Other coagulation factor concentrate

Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐Yes ☐No ☐

If other coagulation factor concentrate, which?

Did any of the above treatments include repeated doses?

Yes ☐No ☐

Please indicate volumes used for each product.

In which NHS hospital(s) did the deceased person receive the products listed before September 1991?

If none of the products listed above was used to treat the deceased person before September 1991, do you think it is probable that the applicant's Hepatitis C infection was caused through treatment with NHS blood or blood products received before September 1991?

Yes ☐

No ☐

If 'Yes', please provide details

PLEASE PROVIDE A COPY OF MEDICAL RECORDS CONFIRMING THE ANSWERS PROVIDED IN SECTION 4

If Section 4 has been completed and the applicant's source of infection is likely to have been a blood transfusion(s), rather than blood products, please complete Section 5(A)

Otherwise, if Section 4 has been completed, please go straight to Section 5(B)

SECTION 5(A)

TO CONFIRM THAT INFECTION MOST PROBABLY
AROSE THROUGH NHS TREATMENT

On which date is it believed that infection (e.g. via a blood transfusion) occurred?

In what NHS hospital or other facility is it believed infection occurred? (If the deceased person had more than one blood transfusion or tissue transplant please list all the hospitals or facilities where they took place)

Please specify under what circumstances is it believed that infection occurred? (e.g. during surgical procedures, A&E treatment, etc.)

Do any records exist of the possible occasion(s) of infection and of any symptoms of infection?

Yes ☐No ☐

If 'Yes', please specify and enclose a copy of the relevant records.

Were any of the following used to treat the deceased person before September 1991?

• Albumin	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
• Intravenous immunoglobulin	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
• Plasma/FFP	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
• Bone marrow	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>
• Whole blood or components (including platelets, red cells, neutrophils etc.)	Yes	<input type="checkbox"/>	No	<input type="checkbox"/>

If so, for what purpose and did the treatment involve repeated doses? (please indicate volumes used for each product)

Does any evidence exist of any other possible source of infection?
(e.g. treatment with other blood products or tissue, etc.)

Yes ☐

No ☐

If 'Yes', please specify

If the date of infection cannot be proved, do you think it is probable
that infection occurred before September 1991?

Yes ☐

No ☐

If 'Yes', please specify

SECTION 5(B)

OTHER POSSIBLE SOURCES OF INFECTION

Based on evidence or your experience, has the deceased person ever been treated for, or been involved with injecting drug use? (This could include living with, or being in a sexual relationship with, a person who injects or injected drugs)

Yes ☐No ☐

If 'Yes', please provide further details

Had the deceased person ever received hospital treatment outside the UK?

Yes ☐No ☐

If 'Yes', please confirm what treatment, where and when?

Is there any other evidence that might affect the eligibility of the Deceased person for payment?

Yes ☐No ☐

If 'Yes', please specify

In your opinion, is it probable that
the deceased persons HCV infection was
acquired as a consequence of NHS treatment received before
September 1991?

Yes ☐

No ☐

If 'No', please give your reasons

SECTION 6

LIVER TRANSPLANTATION AND LIVER CANCER

Was the deceased person on the waiting list for a transplant?

Yes ☐

No ☐

Had the deceased person undergone a liver transplantation?

Yes ☐

No ☐

If 'Yes', what was the date of the transplantation?

Had the deceased person developed primary liver cancer?

Yes ☐

No ☐

If 'Yes', give supporting evidence in the space below:

If the deceased person has undergone a liver transplantation, was on the waiting list for a transplant, or had developed primary liver cancer, there is no need to complete Sections 7-11.

SECTION 7

LIVER HISTOLOGY

Where a liver biopsy has already been undertaken as part of the deceased person's clinical management, please give the following details.

Date of Biopsy:

Details of histology report and diagnosis reached:

If there is histological evidence of cirrhosis, there is no need to complete Sections 8-11.

SECTION 8

B-CELL NON-HODGKIN'S LYMPHOMA

Had the deceased person developed B-cell non-Hodgkin's lymphoma? Yes ☐ No ☐

If 'Yes', please give supporting evidence in the space below:

If the deceased person had developed B-cell non-Hodgkin's lymphoma, there is no need to complete Sections 9-11.

SECTION 9**SIMPLE INDICES PREDICTIVE CIRRHOSIS**

This section is to be completed for a deceased person for whom a liver biopsy has not been performed, or without recent liver histology. The chosen indices require recent and repeatable measurements (two samples not less than three months apart) of the two liver enzymes, aspartate aminotransferase (AST) and alanine aminotransferase (ALT), and also the platelet count.

(Note: if there are factors which could potentially affect the AST, ALT or platelet levels in this applicant, other than fibrosis, please indicate what these might be in Section 7. If the influencing factor is more recent, for instance because the applicant is/was undergoing antiviral therapy, then please either use blood results taken before or after the course of treatment and/or complete Sections 7 and 8).

	First Test Result	Second Test Result	Upper Limit of Normal (ULN)
Date Test Performed			
AST (IU/L)			
ALT (IU/L)			
Platelets x 10 ⁹ /L			

CALCULATED INDICES

	First Measurement	Second Measurement
APRI		
AST/ALT Ratio		

For further guidance on these indices, see page 6 of this form. With regards to the payment for Advanced Hepatitis C, an APRI ≥ 2.0 together with an AST/ALT ≥ 1.0 will be accepted as presumptive evidence for cirrhosis.

If both of these indices are at or above the specified cut-off values, there is no need to complete Sections 10-11.

If these indices give discordant results, or both are below the specified cut-off values, please complete Sections 10 and 11.

SECTION 10**OTHER INFORMATION**

(Note: Any signs of portal hypertension and/or evidence of episodes of hepatic decompensation should be mentioned in this section).

(I) CLINICAL STATUS

Clinical status and findings on physical examination:

--

(II) OTHER BIOCHEMICAL AND HAEMATOLOGICAL TESTS (WHERE AVAILABLE)

Date of Test:

	Result	Normal Range	
Bilirubin			µmol/litre
Albumin			g/l
Globulin			g/l
Alkaline phosphatase			IU/L
Alpha-fetoprotein			IU/ml

Prothrombin time		Secs
(Give normal range for laboratory)		Secs

Any special tests undertaken that may predict the degree of fibrosis or presence of cirrhosis

Some clinicians may have used other tests as markers of fibrosis (e.g. hyaluronic acid). Any such tests undertaken should be described below, stating the particular test(s) used, results obtained and the basis for their interpretation:

--

(III) ABDOMINAL ULTRASOUND (OF LIVER, SPLEEN)

Date of Test:

Report:

(IV) TRANSIENT ELASTOGRAPHY (e.g. FibroScan®)

Date of Test:

Report:

(Note: This test should be undertaken in the fasting state. Please provide details of the deceased person's Body Mass Index (BMI), alcohol intake and whether they have diabetes, as these are known to affect transient elastography readings. If you have not already done so in Section 6, please also provide an ALT result from the time of the transient elastography reading as inflammation/necrosis can also influence liver stiffness independently of fibrosis. If this investigation is the sole evidence for cirrhosis please provide original reports of all Fibroscan tests undertaken over the last three years).

(V) OTHER RADIOLOGICAL EXAMINATIONS (e.g. MRI, CAT SCAN)

Date of Test:

Report:

(VI) ENDOSCOPY

Date of Test:

Report:

(VII) OTHER

Report any other tests that may be relevant:

If Section 10 has been completed, please also complete Section 11.

SECTION 11

OVERALL CLINICAL OPINION

This section must be completed in respect of a deceased person where the application is relying on information provided in Section 10 as a basis for the application. It seeks an overall clinical view as to whether it is probable that the deceased person has developed cirrhosis based on the evidence provided in Section 10.

Clinical Assessment:

Thank you for completing this form. The form and all supporting documents must be sent directly to the Wales Infected Blood Support Scheme at:

Wales Infected Blood Support Scheme
Velindre Cancer Centre
Velindre Road
Whitchurch
Cardiff
CF14 2TL